Evolus Posts 13% Revenue Growth, Fourth Straight Positive Adjusted EBITDA, Reaffirms 2026 Outlook
EOLS sits 94% above its 52-week low of $3.86.
Summary
Evolus reported Q3 2026 net revenue of $78.0 million, up 13% year-over-year, with global toxin revenue up about 11% and the HA gel portfolio up nearly 40%. Adjusted EBITDA came in at $1.2 million versus a $3.1 million loss a year ago — the fourth straight positive quarter — and GAAP operating loss narrowed to $8.4 million from $11.5 million, with a quarterly loss of $12.5 million, or 19 cents a share. Management reaffirmed full-year 2026 revenue of $330-337 million (11-13% growth) and trimmed non-GAAP operating expense guidance to $210-213 million from $212-216 million, a modest tightening of cost expectations. The quarter's growth decelerated from the 21% posted in Q2, and the company still carries a $37.8 million stockholders' deficit with $41.7 million in cash, so liquidity remains tight despite roughly $120 million of non-dilutive capacity. The next specific item is the anticipated FDA approval of Evolysse Sculpt in Q4 2026, which carries no revenue in the current 2026 outlook.
At the time of this announcement, EOLS was trading at $7.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $493.4M. The 52-week trading range was $3.86 to $9.31. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.